Mangoceuticals, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Mangoceuticals, Inc. has an operating margin of -1294.4%, meaning the company retains $-1294 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1260.3% the prior year.
Mangoceuticals, Inc.'s revenue declined 15.8% year-over-year, from $731K to $616K. This contraction results in a growth score of 0/100.
Mangoceuticals, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Mangoceuticals, Inc.'s current ratio of 0.05 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
Mangoceuticals, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Mangoceuticals, Inc. generates $0.56 in operating cash flow (-$4.9M OCF vs -$8.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Mangoceuticals, Inc. earns $-581.9 in operating income for every $1 of interest expense (-$8.0M vs $14K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Mangoceuticals, Inc. (MGRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Mangoceuticals, Inc. generated $616K in revenue in fiscal year 2024. This represents a decrease of 15.8% from the prior year.
Mangoceuticals, Inc.'s EBITDA was -$8.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.4% from the prior year.
Mangoceuticals, Inc. reported -$8.7M in net income in fiscal year 2024. This represents an increase of 5.5% from the prior year.
Mangoceuticals, Inc. earned $-4.84 per diluted share (EPS) in fiscal year 2024. This represents an increase of 43.6% from the prior year.
Mangoceuticals, Inc. held $59K in cash against $0 in long-term debt as of fiscal year 2024.
Mangoceuticals, Inc. had 3M shares outstanding in fiscal year 2024. This represents an increase of 127.3% from the prior year.
Mangoceuticals, Inc.'s gross margin was 61.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.
Mangoceuticals, Inc.'s operating margin was -1294.4% in fiscal year 2024, reflecting core business profitability. This is down 34.1 percentage points from the prior year.
Mangoceuticals, Inc.'s net profit margin was -1413.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 154.2 percentage points from the prior year.
MGRX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84K-49.9% | $168K+53.8% | $109K+3.9% | $105K-35.5% | $163K-23.8% | $214K-12.4% | $244K-0.3% | $245K |
| Cost of Revenue | $2K-87.5% | $19K-23.9% | $25K+16.0% | $21K-28.1% | $30K+42.7% | $21K-61.0% | $53K+2.2% | $52K |
| Gross Profit | $51K-43.4% | $90K+44.9% | $62K-22.5% | $80K+14.8% | $70K-52.7% | $147K+3.4% | $143K-1.4% | $145K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $311K-75.0% | $1.2M-19.3% | $1.5M+80.6% | $854K+0.4% | $851K+10.2% | $772K-62.8% | $2.1M+281.2% | $545K |
| Operating Income | -$7.5M-43.2% | -$5.3M-8.6% | -$4.9M-189.3% | -$1.7M+22.6% | -$2.2M+8.4% | -$2.4M+7.8% | -$2.6M-42.7% | -$1.8M |
| Interest Expense | $76K+249.5% | $22K+258.4% | -$14K | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$7.6M-40.7% | -$5.4M-11.9% | -$4.8M-148.4% | -$1.9M+18.5% | -$2.4M-1.0% | -$2.4M+7.8% | -$2.6M-42.7% | -$1.8M |
| EPS (Diluted) | $-0.69-21.1% | $-0.57+55.8% | $-1.29-55.4% | $-0.83 | $-1.37+8.7% | $-1.50 | $-6.51 | $-1.70 |
MGRX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.5M-20.7% | $20.8M-4.2% | $21.8M+41.5% | $15.4M+0.9% | $15.2M+4954.9% | $301K-71.3% | $1.1M-34.1% | $1.6M |
| Current Assets | $598K+407.1% | $118K-33.2% | $177K+133.7% | $76K-85.4% | $518K+476.3% | $90K-89.2% | $835K-37.8% | $1.3M |
| Cash & Equivalents | $481K+376.4% | $101K+32.1% | $76K+30.4% | $59K-88.0% | $490K+3103.2% | $15K-97.9% | $739K-40.2% | $1.2M |
| Inventory | N/A | N/A | N/A | $13K-5.7% | $14K-3.0% | $14K-21.9% | $19K-14.3% | $22K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $804K-49.8% | $1.6M+6.5% | $1.5M+5.5% | $1.4M+1.2% | $1.4M+11.8% | $1.3M+356.4% | $276K+14.7% | $241K |
| Current Liabilities | $804K-49.8% | $1.6M+6.5% | $1.5M+5.5% | $1.4M+3.4% | $1.4M+13.7% | $1.2M+474.3% | $211K+32.6% | $159K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $15.7M-18.3% | $19.2M-5.0% | $20.3M+45.2% | $13.9M+0.8% | $13.8M+1543.0% | -$958K-223.7% | $775K-42.8% | $1.4M |
| Retained Earnings | -$37.9M-19.7% | -$31.6M-22.0% | -$25.9M-29.7% | -$20.0M-25.1% | -$16.0M-17.6% | -$13.6M-21.1% | -$11.2M-29.7% | -$8.7M |
MGRX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M+1.2% | -$1.3M+44.8% | -$2.3M-101.4% | -$1.1M+28.4% | -$1.6M-59.1% | -$991K+41.6% | -$1.7M+0.8% | -$1.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$1.7M+0.8% | -$1.7M |
| Investing Cash Flow | N/A | N/A | N/A | $0 | N/A | N/A | $0 | $0 |
| Financing Cash Flow | $1.6M+26.6% | $1.3M-43.9% | $2.3M+103.6% | $1.1M-43.5% | $2.0M+643.3% | $268K-77.7% | $1.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MGRX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.4%+6.9pp | 53.5%-3.3pp | 56.8%-19.3pp | 76.1%+33.3pp | 42.8%-26.1pp | 68.8%+10.5pp | 58.4%-0.6pp | 59.0% |
| Operating Margin | -8953.4%-5819.5pp | -3134.0%+1306.0pp | -4440.0%-2846.0pp | -1594.0%-264.9pp | -1329.1%-223.3pp | -1105.9%-55.0pp | -1050.9%-316.9pp | -734.0% |
| Net Margin | -9042.8%-5821.2pp | -3221.6%+1205.8pp | -4427.4%-2576.2pp | -1851.2%-385.8pp | -1465.4%-359.5pp | -1105.9%-55.0pp | -1050.9%-316.9pp | -734.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -46.1%-20.1pp | -26.0%-3.7pp | -22.3%-9.6pp | -12.7%+3.0pp | -15.7%+769.7pp | -785.4%-541.0pp | -244.4%-131.6pp | -112.8% |
| Current Ratio | 0.74+0.7 | 0.07-0.0 | 0.12+0.1 | 0.05-0.3 | 0.38+0.3 | 0.07-3.9 | 3.96-4.5 | 8.44 |
| Debt-to-Equity | 0.05-0.0 | 0.080.0 | 0.07-0.0 | 0.100.0 | 0.10+1.4 | -1.31-1.7 | 0.36+0.2 | 0.18 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -694.7%+3.1pp | -697.8% |
Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Mangoceuticals, Inc.'s annual revenue?
Mangoceuticals, Inc. (MGRX) reported $616K in total revenue for fiscal year 2024. This represents a -15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Mangoceuticals, Inc.'s revenue growing?
Mangoceuticals, Inc. (MGRX) revenue declined by 15.8% year-over-year, from $731K to $616K in fiscal year 2024.
Is Mangoceuticals, Inc. profitable?
No, Mangoceuticals, Inc. (MGRX) reported a net income of -$8.7M in fiscal year 2024, with a net profit margin of -1413.6%.
What is Mangoceuticals, Inc.'s earnings per share (EPS)?
Mangoceuticals, Inc. (MGRX) reported diluted earnings per share of $-4.84 for fiscal year 2024. This represents a 43.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mangoceuticals, Inc.'s EBITDA?
Mangoceuticals, Inc. (MGRX) had EBITDA of -$8.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mangoceuticals, Inc.'s gross margin?
Mangoceuticals, Inc. (MGRX) had a gross margin of 61.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Mangoceuticals, Inc.'s operating margin?
Mangoceuticals, Inc. (MGRX) had an operating margin of -1294.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Mangoceuticals, Inc.'s net profit margin?
Mangoceuticals, Inc. (MGRX) had a net profit margin of -1413.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Mangoceuticals, Inc.'s operating cash flow?
Mangoceuticals, Inc. (MGRX) generated -$4.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mangoceuticals, Inc.'s total assets?
Mangoceuticals, Inc. (MGRX) had $15.4M in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Mangoceuticals, Inc. have outstanding?
Mangoceuticals, Inc. (MGRX) had 3M shares outstanding as of fiscal year 2024.
What is Mangoceuticals, Inc.'s current ratio?
Mangoceuticals, Inc. (MGRX) had a current ratio of 0.05 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Mangoceuticals, Inc.'s debt-to-equity ratio?
Mangoceuticals, Inc. (MGRX) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mangoceuticals, Inc.'s return on assets (ROA)?
Mangoceuticals, Inc. (MGRX) had a return on assets of -56.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mangoceuticals, Inc.'s cash runway?
Based on fiscal year 2024 data, Mangoceuticals, Inc. (MGRX) had $59K in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mangoceuticals, Inc.'s Piotroski F-Score?
Mangoceuticals, Inc. (MGRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mangoceuticals, Inc.'s earnings high quality?
Mangoceuticals, Inc. (MGRX) has an earnings quality ratio of 0.56x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Mangoceuticals, Inc. cover its interest payments?
Mangoceuticals, Inc. (MGRX) has an interest coverage ratio of -581.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Mangoceuticals, Inc.?
Mangoceuticals, Inc. (MGRX) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.